antibody platform
Discovery
XOMA’s ADAPT™ Platform utilizes high diversity and state of the art phage display libraries combined with flexible antibody expression options. In addition, XOMA employs a range of proprietary panning and screening methods developed through years of antibody discovery experience.
XOMA has some of the most diverse phage display antibody libraries available:
- Picomolar affinity antibodies are routinely selected
- Antibody fragments with different target specificities and diverse epitope coverage can be isolated
Integrated display platforms yield development advantages:
XOMA’s multiple custom antibody phage library and inter-platform compatible vectors enable rapid transition from phage to yeast or mammalian antibody display. Development of proprietary bacterial strains, improved cell-based panning methods, and antibody optimization technologies (OptimX™) enhance the quality of our antibody pipeline. Our custom software package, including SeqAgent™ and XAbTracker™, allows rapid sequence analysis and hit-to-lead clone tracking. Permanent and transient expression systems enable expression and manufacturing optimization. XOMA’s complete antibody discovery package increases the quality and speed of therapeutic antibody discovery.
